Veracyte VCYT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $517.15M+16.0% | $445.76M+23.5% | $361.05M+21.8% | $296.54M+35.1% | ||
| —— | —— | —— | —— | ||
| $362.53M+21.6% | $298.15M+29.8% | $229.68M+30.7% | $175.68M— | ||
| 70.1%+3.2pp | 66.9%+3.3pp | 63.6%+4.4pp | 59.2%— | ||
| $70.81M+2.2% | $69.29M+20.9% | $57.31M+41.1% | $40.6M+36.1% | ||
| $100.17M+5.0% | $95.43M-6.0% | $101.49M+4.0% | $97.56M+22.2% | ||
| $110.78M+0.2% | $110.61M+28.3% | $86.23M+12.7% | $76.52M-24.5% | ||
| —— | —— | —— | —— | ||
| $304.76M+8.1% | $282M-18.6% | $346.51M— | —— | ||
| $57.78M+258% | $16.14M+119% | -$85.8M-109% | -$41.08M+49.8% | ||
| 11.2%+7.6pp | 3.6%+27.4pp | -23.8%-9.9pp | -13.9%+23.5pp | ||
| $10.42M+0.9% | $10.33M+12.5% | $9.18M+97.3% | $4.65M+1,732% | ||
| $68.2M+165% | $25.74M+134% | -$76.61M-110% | -$36.43M+55.4% | ||
| —— | —— | -$2.21M-1,760% | $133K+102% | ||
| $66.35M+175% | $24.14M+132% | -$74.4M-104% | -$36.56M+51.6% | ||
| 12.8%+7.4pp | 5.4%+26.0pp | -20.6%-8.3pp | -12.3%+22.1pp | ||
| $0.82+173% | $0.30+129% | -$1.02-104% | -$0.50+55.8% | ||
| $79.19M+100.0% | $39.6M+168% | -$58.61M-287% | -$15.15M+75.7% | ||
| 15.3%+6.4pp | 8.9%+25.1pp | -16.2%-11.1pp | -5.1%+23.3pp | ||
| $57.78M+258% | $16.14M+119% | -$85.8M-109% | -$41.08M+49.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Veracyte's profit margins?
- Gross margin is 70.9% and operating margin is 14.3%, with a 16.2% net margin.
- Where does Veracyte's income statement data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.